Brian Lian, Viking Therapeutics CEO
Viking soars on early-stage weight loss data as it maps out PhII
Viking Therapeutics will enter the next phase of the GLP-1 weight loss race, as the small biotech touted early data showing its investigational drug led …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
